Werewolf Therapeutics (HOWL) Cash from Investing Activities (2020 - 2024)
Werewolf Therapeutics (HOWL) posted quarterly Cash from Investing Activities of -$123000.0 for Q4 2024, up 37.88% year-over-year from -$89208.8 in Q1 2024, and down 4000.0% on a QoQ basis from -$3000.0 in Q3 2024.
Werewolf Therapeutics (HOWL) Cash from Investing Activities (2020 - 2024) Analysis & Trends
Werewolf Therapeutics has reported Cash from Investing Activities for 5 years, with the latest figure at -$123000.0 in Q4 2024.
- Cash from Investing Activities for Q4 2024 came in at -$123000.0, up 37.88% year-over-year; the trailing twelve-month figure through Sep 2025 was -$123000.0 (up 62.61% YoY), and the FY2024 annual result was -$254000.0, up 66.97% from the prior year.
- Cash from Investing Activities declined to -$123000.0 in Q4 2024, from -$3000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$3000.0 in Q3 2024 and troughed at -$2.0 million in Q3 2022.
- A 5-year average of -$284600.0 and a median of -$117000.0 in 2021 frame the typical range for Cash from Investing Activities.
- The widest annual swing landed in 2021, when Cash from Investing Activities slumped 2922.22%; it then surged 98.64% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$9000.0 in 2020, then slumped by 2922.22% to -$272000.0 in 2021, then tumbled by 90.44% to -$518000.0 in 2022, then soared by 61.78% to -$198000.0 in 2023, then jumped by 37.88% to -$123000.0 in 2024.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$123000.0 in Q4 2024, -$3000.0 in Q3 2024, and -$17000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -123,000.00 |
| Dec 31, 2024 | -123,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -17,000.00 |
| Jun 30, 2024 | -17,000.00 |
| Mar 31, 2024 | -111,000.00 |
| Mar 31, 2024 | -111,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Sep 30, 2023 | -221,000.00 |
| Sep 30, 2023 | -221,000.00 |
| Jun 30, 2023 | -182,000.00 |
| Jun 30, 2023 | -182,000.00 |
| Mar 31, 2023 | -168,000.00 |
| Mar 31, 2023 | -168,000.00 |
| Dec 31, 2022 | -518,000.00 |
| Dec 31, 2022 | -518,000.00 |
| Sep 30, 2022 | -1.95 Mn |
| Sep 30, 2022 | -1.95 Mn |